Effects of specific signal transduction inhibitors on increased permeability across rat endothelial monolayers induced by neuropeptide Y or VEGF

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Kurimoto, Nakako ^a   Nan, Yong Shan ^b   Chen, Zhi Yong ^b   Feng, Guo Gang ^a   Komatsu, Toru ^a   Kandatsu, Nobuhisa ^a   Ko, Junken ^a   Kawai, Norio ^a   Ishikawa, Naohisa ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abl; Hypoxia; Myosin light chain kinase; Protein kinase C; STI571; Y3 receptor

Indexed keywords

1 (5 CHLORO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ABELSON KINASE; ABL TYROSINE KINASE INHIBITOR; ALBUMIN; BISINDOLYLMALEIMIDE; CALMODULIN DEPENDENT KINASE INHIBITOR; DY 9760E; ENZYME INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; IMATINIB; MYOSIN LIGHT CHAIN KINASE INHIBITOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y3 RECEPTOR; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR SUBTYPE; SIGNAL TRANSDUCTION INHIBITOR; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL HYPOXIA; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOSE TIME EFFECT RELATION; DRUG SPECIFICITY; ENDOTHELIUM CELL; ENZYME INHIBITION; INHIBITION KINETICS; INTRACELLULAR TRANSPORT; MALE; MONOLAYER CULTURE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; CAPILLARY PERMEABILITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MALE; NEUROPEPTIDE Y; OSMOLAR CONCENTRATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042628464     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00922.2003     Document Type: Article

References (36)

1. 2 receptors. Eur J Pharmacol 294: 391-401, 1995.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, and Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 16: 139-145, 2000.
3. Buchdunger E, O'Reilly T, and Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 38 Suppl 5: S28-S36, 2002.
4. Colmers WF and Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci 17: 373-379, 1994.
5. Dudek SM and Garcia JGN. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 91: 1487-1500, 2001.
6. Duesler JG Jr, Daly RN, and Hieble JP. Studies on the mechanism of neuropeptide Y induced potentiation of neurogenic vasoconstriction in the isolated rabbit ear artery. Am J Hypertens 3: 796-799, 1990.
7. Ferrara N and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
8. Ferrara N and Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858, 1989.
9. Fisher S, Renz D, Wiesnet M, Schaper W, and Karliczek GF. Hypothermia abolishes hypoxia-induced hyperpermeability in brain microvessel endothelial cells. Brain Res Mol Brain Res 74: 135-144, 1999.
10. Folkman J and Klagsbrun M. Angiogenic factors. Science 235: 442-447, 1987.
11. Gomperts BD, Kramer IM, and Tatham PER. Signaling pathways operated by receptor protein tyrosine kinases. In: Signal Transduction, edited by Gomperts BD, Kramer IM, and Tatham PER. London: Academic, 2002, p. 257-282.
12. Hirabayashi A, Nishiwaki K, Shimada Y, and Ishikawa N. Role of neuropeptide Y and its receptor subtypes in neurogenic pulmonary edema. Eur J Pharmacol 296: 297-305, 1996.
13. Krystal GW, Honsawek S, Litz J, and Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
14. Lum H and Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 280: C719-C741, 2001.
15. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, and Westfall T. Recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50: 143-150, 1998.
16. Mukhopadhyay D, Nagy JA, Manseau EJ, and Dvorak HF. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 58: 1278-1284, 1998.
17. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, and Isner JM. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195, 1995.
18. Nan YS, Feng GG, Hotta Y, Nishiwaki K, Shimada Y, Ishikawa A, Kurimoto N, and Ishikawa N. Neuropeptide Y enhances permeability across a rat aortic endothelial cell monolayer. Am J Physiol Heart Circ Physiol 286: H1027-H1033, 2004.
19. Noll T, Hempel A, and Piper HM. Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers. Am J Physiol Heart Circ Physiol 271: H1878-H1883, 1996.
20. Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100, 2002.
21. Physiological Society of Japan. Guiding principles for the care and use of animals in the field of physiological sciences. J Physiol Soc Jpn 64: 143-146, 2002.
22. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
23. Shibuya M, Ito N, and Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 237: 59-83, 1999.
24. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, and Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524, 1990.
25. Snedecor GW and Cochran WG. Statistical Methods. Ames, IA: Iowa State University Press, 1967.
26. Stasek JE Jr, Patterson CE, and Garcia JG. Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol 153: 62-75, 1992.
27. 2+ signaling. Pflügers Arch 438: 612-620, 1999.
28. Takahashi T, Ueno H, and Shibuya M. VEGF activates protein kinase C-dependent but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230, 1999.
29. Tallquist MD, Soriano P, and Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 18: 7917-7932, 1999.
30. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, and Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase kinase. Oncogene 9: 1677-1683, 1991.
31. Vries CD, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
32. Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, and Stacker SA. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 96: 3071-3076, 1999.
33. Woodring PJ, Hunter T, and Wang JYJ. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 116: 2613-2626, 2003.
34. Woodring PJ, Litwack ED, O'Leary DD, Lucero GR, Wang JY, and Hunter T. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 156: 879-892, 2002.
35. Wu HM, Yuan Y, Zawieja DC, Tinsley J, and Granger HJ. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol Heart Circ Physiol 276: H535-H542, 1999.
36. Zukawska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, and Grant DS. Neuro-peptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83: 187-195, 1998.